{"id":"cj-30001-cj-30002","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":{"chemblId":"CHEMBL1671898","moleculeType":"Small molecule","molecularWeight":"377.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By simultaneously activating GLP-1 and glucagon receptors, this dual agonist enhances insulin secretion, reduces glucagon secretion in a glucose-dependent manner, and increases energy expenditure. This dual mechanism is designed to provide superior glycemic control and greater weight reduction compared to GLP-1 monotherapy in patients with type 2 diabetes.","oneSentence":"CJ-30001/CJ-30002 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:00.866Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01370707","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2011-04","conditions":"Diabetes Mellitus","enrollment":187}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CJ-30001/CJ-30002","genericName":"CJ-30001/CJ-30002","companyName":"HK inno.N Corporation","companyId":"hk-inno-n-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CJ-30001/CJ-30002 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}